Richard C Condit
Overview
Explore the profile of Richard C Condit including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
864
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kunert N, Zailaa J, Herrmann V, Muller-Landau H, Wright S, Perez R, et al.
New Phytol
. 2021 Jan;
230(2):485-496.
PMID: 33449384
The effects of climate change on tropical forests will depend on how diverse tropical tree species respond to drought. Current distributions of evergreen and deciduous tree species across local and...
2.
Volkmann A, Williamson A, Weidenthaler H, Meyer T, Robertson J, Excler J, et al.
Vaccine
. 2020 Oct;
39(22):3067-3080.
PMID: 33077299
The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to evaluate the safety and characteristics of live, recombinant viral vector vaccines. The Modified Vaccinia Ankara (MVA) vector...
3.
Gurwith M, Condit R, Excler J, Robertson J, Kim D, Fast P, et al.
Vaccine
. 2020 Oct;
38(49):7702-7707.
PMID: 33070999
Several live-attenuated viral vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the...
4.
Condit R, Kim D, Robertson J, Excler J, Gurwith M, P Monath T, et al.
Vaccine
. 2020 Sep;
38(49):7708-7715.
PMID: 32907759
Many of the vaccines under development for COVID-19 involve the use of viral vectors. The Brighton Collaboration Benefit-Risk Assessment of Vaccines by Technology (BRAVATO, formerly the Viral Vector Vaccine Safety...
5.
Kochhar S, Excler J, Kim D, Robertson J, Fast P, Condit R, et al.
Vaccine
. 2020 Aug;
38(39):6184-6189.
PMID: 32747214
Inactivated viral vaccines have long been used in humans for diseases of global health threat and are now among the vaccines for COVID-19 under development. The Brighton Collaboration Viral Vector...
6.
Kochhar S, Kim D, Excler J, Condit R, Robertson J, Drew S, et al.
Vaccine
. 2020 Jul;
38(35):5734-5739.
PMID: 32653276
Several protein vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key...
7.
Kim D, Robertson J, Excler J, Condit R, Fast P, Gurwith M, et al.
Vaccine
. 2020 Jun;
38(34):5556-5561.
PMID: 32571717
Nucleic acid (DNA and RNA) vaccines are among the most advanced vaccines for COVID-19 under development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized...
8.
Knoll L, Hogan D, Leong J, Heitman J, Condit R
PLoS Pathog
. 2018 Mar;
14(3):e1006915.
PMID: 29596508
No abstract available.
9.
Gates S, Condit R, Moussatche N, Stewart B, Malkin A, Weber P
Anal Chem
. 2018 Jan;
90(3):1613-1620.
PMID: 29295620
High-lateral-resolution secondary ion mass spectrometry (SIMS) has the potential to provide functional and depth resolved information from small biological structures, such as viral particles (virions) and phage, but sputter rate...
10.